|
CA2119155C
(en)
*
|
1991-10-18 |
1999-06-15 |
Dennis Paul Phillion |
Fungicides for the control of take-all disease of plants
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
JP2002540203A
(ja)
|
1999-03-29 |
2002-11-26 |
ニューロゲン コーポレイション |
Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
|
|
WO2000064877A1
(en)
|
1999-04-26 |
2000-11-02 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
ES2254688T3
(es)
*
|
2001-04-11 |
2006-06-16 |
Glaxosmithkline S.P.A. |
Derivados de quinolina-4-carboxamida como antagonistas de los receptores nk-3 y nk-2.
|
|
AU2002259147A1
(en)
*
|
2001-05-08 |
2002-11-18 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
SG168407A1
(en)
|
2003-01-28 |
2011-02-28 |
Ironwood Pharmaceuticals Inc |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
GB0303086D0
(en)
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2005304962B2
(en)
*
|
2004-11-09 |
2009-11-19 |
Smithkline Beecham Corporation |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
JP2009504641A
(ja)
*
|
2005-08-11 |
2009-02-05 |
アストラゼネカ・アクチエボラーグ |
Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW200804288A
(en)
*
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
EP2527360B1
(en)
|
2007-06-04 |
2015-10-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
KR20100075568A
(ko)
*
|
2007-09-28 |
2010-07-02 |
글락소스미스클라인 엘엘씨 |
글리코겐 포스포릴라아제 억제제 화합물 및 이의 약제 조성물
|
|
KR20100087300A
(ko)
*
|
2007-09-28 |
2010-08-04 |
글락소스미스클라인 엘엘씨 |
글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
SI2384318T1
(en)
|
2008-12-31 |
2018-03-30 |
Ardelyx, Inc. |
MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
MX366293B
(es)
|
2012-08-21 |
2019-07-04 |
Ardelyx Inc |
Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
LT2983667T
(lt)
|
2013-04-12 |
2019-07-10 |
Ardelyx, Inc. |
Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
|
|
CA2909752A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
SI3004138T1
(sl)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Limited |
Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
EA201991676A1
(ru)
|
2017-01-09 |
2020-01-30 |
Арделикс, Инк. |
Ингибиторы nhe-опосредованного антипорта
|
|
CA3049678A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|